6.74
0.40 (6.31%)
| Previous Close | 6.34 |
| Open | 6.35 |
| Volume | 631,028 |
| Avg. Volume (3M) | 1,078,211 |
| Market Cap | 417,370,112 |
| Price / Sales | 2.12 |
| Price / Book | 0.740 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.63 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Anchorage Capital Group, L.L.C. | 31 Dec 2025 | 1,746,363 |
| Forbes J M & Co Llp | 31 Dec 2025 | 1,040,441 |
| Prescott Group Capital Management, L.L.C. | 31 Dec 2025 | 541,845 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (TD Cowen, 78.04%) | Buy |
| Median | 8.50 (26.11%) | |
| Low | 5.00 (BTIG, -25.82%) | Sell |
| Average | 8.50 (26.11%) | |
| Total | 1 Buy, 1 Sell | |
| Avg. Price @ Call | 7.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 12 Mar 2026 | 5.00 (-25.82%) | Sell | 6.74 |
| TD Cowen | 08 Jan 2026 | 12.00 (78.04%) | Buy | 9.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark |
| 13 Jan 2026 | Announcement | Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference |
| 22 Dec 2025 | Announcement | Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach |
| 17 Dec 2025 | Announcement | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |